Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
2.280
+0.040 (1.79%)
At close: May 22, 2025, 4:00 PM
2.300
+0.020 (0.88%)
After-hours: May 22, 2025, 6:41 PM EDT
Mereo BioPharma Group Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Mereo BioPharma Group stock ranges from a low of $7.00 to a high of $10. The average analyst price target of $7.71 forecasts a 238.16% increase in the stock price over the next year.
Price Target: $7.71 (+238.16%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mereo BioPharma Group stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +207.02% | May 13, 2025 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +207.02% | Apr 9, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $7 | Buy | Initiates | $7 | +207.02% | Mar 27, 2025 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +207.02% | Mar 26, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +207.02% | Mar 18, 2025 |
Financial Forecast
Revenue This Year
23.67M
Revenue Next Year
36.66M
from 23.67M
Increased by 54.91%
EPS This Year
-0.05
from -0.29
EPS Next Year
-0.02
from -0.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 101.0M | 75.8M | 109.7M | ||
| Avg | 23.7M | 36.7M | 65.4M | ||
| Low | n/a | 988,751 | 18.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 220.2% | 199.1% | ||
| Avg | - | 54.9% | 78.5% | ||
| Low | - | -95.8% | -49.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.02 | 0.06 | 0.02 | ||
| Avg | -0.05 | -0.02 | -0.03 | ||
| Low | -0.07 | -0.07 | -0.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.